Akita Hirotoshi, Kinoshita Ichiro
Dept. of Medical Oncology, Hokkaido University Graduate School of Medicine, Kita-ku, Sapporo, Japan.
Gan To Kagaku Ryoho. 2008 May;35(5):720-4.
Molecular targeted therapy in combination with chemotherapy or thoracic radiotherapy has been studied in clinical trials. Gefitinib or erlotinib in combination with standard chemotherapy did not improve efficacy on survival over standard chemotherapy alone in chemotherapy-naive patients with advanced NSCLC. On the other hand, bevacizumab in combination with standard chemotherapy improved survival in chemotherapy-naive patients with advanced NSCLC, excluding squamous cell carcinoma. Multi-target tyrosine kinase inhibitors in combination with standard chemotherapy, and anti-EGFR antibodies and EGFR tyrosine kinase inhibitors in combination with thoracic radiotherapy, are under clinical trials.
分子靶向治疗联合化疗或胸部放疗已在临床试验中进行了研究。在未经化疗的晚期非小细胞肺癌患者中，吉非替尼或厄洛替尼联合标准化疗在生存疗效上并未优于单纯标准化疗。另一方面，贝伐单抗联合标准化疗可改善未经化疗的晚期非小细胞肺癌患者（不包括鳞状细胞癌）的生存情况。多靶点酪氨酸激酶抑制剂联合标准化疗，以及抗表皮生长因子受体（EGFR）抗体和EGFR酪氨酸激酶抑制剂联合胸部放疗，均在临床试验中。
